A336040 Stock Overview
TASCOM Co.,Ltd. manufactures and distributes diabetic supplies in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
TASCOM Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,490.00 |
| 52 Week High | ₩10,550.00 |
| 52 Week Low | ₩3,000.00 |
| Beta | 0 |
| 11 Month Change | -28.78% |
| 3 Month Change | -45.38% |
| 1 Year Change | -66.92% |
| 33 Year Change | -85.27% |
| 5 Year Change | n/a |
| Change since IPO | -82.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| A336040 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -1.7% | 6.1% | -2.8% |
| 1Y | -66.9% | 14.9% | -3.4% |
Return vs Industry: A336040 underperformed the KR Medical Equipment industry which returned 14.9% over the past year.
Return vs Market: A336040 underperformed the KR Market which returned -3.4% over the past year.
Price Volatility
| A336040 volatility | |
|---|---|
| A336040 Average Weekly Movement | 10.9% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A336040's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A336040's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | n/a | www.yidobio.com |
TASCOM Co.,Ltd. manufactures and distributes diabetic supplies in South Korea. Its products include blood glucose measurement system-acuraview, BD ultra fine PRO pen needle, syringes-BD ultrafine syringes, Ido sharp container, and Ido safety lancet.
TASCOM Co., Ltd. Fundamentals Summary
| A336040 fundamental statistics | |
|---|---|
| Market cap | ₩13.75b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A336040 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A336040 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A336040 perform over the long term?
See historical performance and comparison